Eyegate (EYEG): H.C. Wainwright Reconfirms Buy Rating Today, Has a Target of $6.0/Share

February 16, 2018 - By Dolores Ford

 Eyegate (EYEG): H.C. Wainwright Reconfirms Buy Rating Today, Has a Target of $6.0/Share

Eyegate (EYEG) Rating Reaffirmed

In a report issued to clients and investors this morning, H.C. Wainwright reiterated their Buy rating on Eyegate (EYEG) shares. The target price per share indicates a possible upside of 837.50 % from company’s last stock close price.

Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) Ratings Coverage

Among 2 analysts covering Eyegate Pharma… (EYEG), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Eyegate Pharma… has $600 highest and $3.0 lowest target. $3’s average target is 368.75% above currents $0.64 stock price. Eyegate Pharma… had 8 analyst reports since April 7, 2016 according to SRatingsIntel. The rating was maintained by H.C. Wainwright on Wednesday, November 15 with “Buy”. On Tuesday, August 8 the stock rating was maintained by H.C. Wainwright with “Buy”. The stock of Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) has “Buy” rating given on Tuesday, December 19 by H.C. Wainwright. The stock has “Buy” rating by Noble Financial on Thursday, April 7. The firm has “Buy” rating given on Tuesday, February 6 by H.C. Wainwright. The stock of Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) earned “Buy” rating by H.C. Wainwright on Wednesday, June 14. The rating was maintained by H.C. Wainwright with “Buy” on Thursday, November 9. As per Wednesday, August 2, the company rating was maintained by H.C. Wainwright.

The stock increased 6.67% or $0.04 during the last trading session, reaching $0.64. About 33,459 shares traded. Eyegate Pharmaceuticals, Inc. (EYEG) has declined 40.33% since February 16, 2017 and is downtrending. It has underperformed by 57.03% the S&P500.

Analysts await Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) to report earnings on February, 22. They expect $-0.26 EPS, up 31.58 % or $0.12 from last year’s $-0.38 per share. After $-0.24 actual EPS reported by Eyegate Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 8.33 % negative EPS growth.

EyeGate Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing drug compositions and drug delivery systems for treating diseases and disorders of the eye. The company has market cap of $11.01 million. The firm is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including the treatment of ocular inflammation and pain in post-surgical cataract patients; and uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea. It currently has negative earnings. It is also developing the EyeGate Ocular Bandage Gel, a topically-applied eye drop formulation that has completed its first-in-man clinical trial for the management of corneal epithelial defects, as well as to accelerate re-epithelization of the ocular surface following surgery, injection, and other traumatic and non-traumatic conditions.

More notable recent Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) news were published by: Globenewswire.com which released: “EyeGate Pharma Enrolls First Patient in Phase 2b Clinical Study of EGP-437 for …” on August 01, 2017, also Streetinsider.com with their article: “Eyegate Pharma (EYEG) Announces Promotion of Sarah Romano to CFO Position” published on January 04, 2018, Streetinsider.com published: “Eyegate Pharma (EYEG) Reports New US Patent for Iontophoretic Delivery of …” on December 19, 2017. More interesting news about Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) were released by: Marketwatch.com and their article: “Eyegate Pharma stock surges 11% after receiving Valeant milestone payment” published on May 22, 2017 as well as Globenewswire.com‘s news article titled: “EyeGate Announces Top-Line Results for Phase 2b Trial of EGP-437 in Cataract …” with publication date: February 05, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.